Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-08-18
2008-08-05
Campell, Bruce (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S001650, C424S278100
Reexamination Certificate
active
07408050
ABSTRACT:
The present invention relates to a modified CpG oligodeoxynucleotide (ODN) which is prepared by coupling a consecutive sequence of deoxyribothymine (dT) to the 3′-terminus of CpG ODN having immunoregularory function, thereby improving immunoactivity of splenocytes, macrophages and peripheral mononuclear cells, and therefore, can be effectively used as a vaccine adjuvant for preventing and treating hepatitis B or an anti-cancer agent. Since the phosphorothioate CpG ODN having the consecutive sequence of dT at its 3′-terminus shows high activity inducing Th-1 immune response and does not elicit in vivo toxicity with guaranteeing its safety, it can be effectively used as a vaccine adjuvant.
REFERENCES:
patent: 2005/0064401 (2005-03-01), Olek et al.
Kim et al., CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model, 2004, Immunology, vol. 112, pp. 117-125.
McCluskie et al., The potential of oligoeoxynucleotides as mucosal and parenteral adjuvants, 2001, Vaccine, vol. 19, pp. 2657-2660.
Miconnet et al., CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide, 2002, The Journal of Immunology, vol. 168, pp. 1212-1218.
Qin et al., CPG ODN Enhances Immunization Effects of Hepatitis B Vaccine in Agen Mice, 2004, Cellular and Molecular Immunology, vol. 1, No. 2, pp. 148-152.
Glebe D., Recent advances in hepatitis B virus research: A German point of view, 2007, World Journal of Gastroenterology, vol. 13, No. 1, pp. 8-13.
Zuckerman J., Vaccination against hepatitis A and B: developments, deployment and delusions, 2006, Current Opinions in Infectious Diseases, vol. 19, pp. 456-459.
Vollmer J., Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9, 2005, Expert Opinion of Biological Therapies, vol. 5, No. 5, pp. 673-682.
Bylund et al., Immunostimulatory DNA induces degranulation and NADPH-oxidase activation in human neutrophils while concomitantly inhibiting chemotaxis and phagocytosis, 2002, European Journal of Immunology, vol. 32, pp. 2847-2856.
Pontarollo et al., Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs, 2002, Veterinary Immunology and Immunopathology, vol. 84, pp. 43-59.
A.M. Krieg, “CPG Motifs in Bacterial DNA and Their Immune Effects”, Annu. Rev. Immunol., vol. 20, pp. 709-760, (2002).
D.M. Klinman et al., “CPG DNA: Recognition by and Activation of Monocytes”, Microbes and Infection, vol. 4, pp. 897-901, (2002).
M. Gursel et al., “CPG Oligodeoxynucleotides Induce Human Monocytes to Mature Into Functional Dendritic Cells”, Eur. J. Immunol., vol. 32, pp. 2617-2622, (2002).
H. Hemmi et al., “The Roles of Toll-Like Receptor 9, MYD88, and DNA-Dependent Protein Kinase Catalytic Subunit in the Effects of Two Distinct CPG DNAs on Dendritic Cell Subsets”, The Journal of Immunology, vol. 170, pp. 3059-3064, (2003).
M. Kerkmann et al., “Activation With CPG-A and CPG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells”, The Journal of Immunology, vol. 170, pp. 4465-4474, (2003).
B.V. Stern et al., “Vaccination With Tumor Peptide In CPG Adjuvant Protects Via IFN-γ-Dependent CD4 Cell Immunity”, The Journal of Immunology, vol. 168, pp. 6099-6105, (2002).
Z.K. Ballas, “Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides With Distinct CPG Motifs”, The Journal of Immunology, vol. 167, pp. 4878-4886, (2001).
K. Heckelsmiller et al., “Peritumoral CPG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model”, The Journal of Immunology, vol. 169, pp. 3892-3899, (2002).
J.E. Wooldridge et al., “Immunostimulatory Oligodeoxynucleotides Containing CPG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma”, Blood, vol. 89, No. 8, pp. 2994-2998, (Apr. 15, 1997).
B. Jahrsdörfer et al., “Immunostimulatory CPG Oligodeoxynucleotides and Antibody Therapy of Cancer”, Seminars in Oncology, vol. 30, No. 4, pp. 476-482, (Aug. 2003).
D.P. Sester, “Phosphorothioate Backbone Modification Modulates Macrophage Activation by CPG DNA”, The Journal of Immunology, vol. 165, pp. 4165-4173, (2000).
Cho Hyun Chul
Kim Soo Kie
Park Seung Kyu
Park Su Jung
Blumel Benjamin P
Campell Bruce
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Yonsei University
LandOfFree
Modified CpG oligodeoxynucleotide with improved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified CpG oligodeoxynucleotide with improved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified CpG oligodeoxynucleotide with improved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015186